
Nkarta, Inc. (NKTX) Stock Forecast & Price Target
Nkarta, Inc. (NKTX) Analyst Ratings
Bulls say
Nkarta Inc. is capitalizing on its innovative allogeneic CAR-NK therapy, which presents significant safety advantages, including potentially lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to traditional autologous CAR-T therapies. The company's unique off-the-shelf NK cell manufacturing capability allows for a less cumbersome treatment regimen, which could enhance patient accessibility and adherence, positioning Nkarta favorably in the evolving cancer therapy landscape. With revenues currently projected from lymphomas but also viewing systemic lupus erythematosus (SLE) as potential upside, Nkarta's future studies could further bolster revenue streams contingent on upcoming positive clinical data.
Bears say
Nkarta Inc's stock outlook is negatively influenced by the discontinuation of its NHL development, which has resulted in the removal of these sales from financial models, thereby contributing to a decline in price target from $22 to $18. The company faces significant risks, including potential safety issues in clinical trials, lower-than-expected efficacy, and increased competition, which may adversely affect its clinical programs. Additionally, with an operating loss of $33.8 million in 3Q24 and projected financing needs of approximately $900 million through 2040, Nkarta's financial health may be at risk, indicating concerns regarding its sustainability and growth prospects.
This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares